Text stringlengths 636 34.6k |
|---|
Drug A is Abaloparatide. Drug B is Acebutolol. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Acebutolol is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Aldesleukin. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Aldesleukin is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Aliskiren. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Abaloparatide is combined with Aliskiren. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Ambrisentan. The severity of the interaction is minor. Abaloparatide may increase the hypotensive activities of Ambrisentan. The use of two drugs that both lower blood pressure may result in a more pronounced hypotensive effect. Abaloparatide is indicated for the treatment of postmeno... |
Drug A is Abaloparatide. Drug B is Amifostine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Amifostine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Amiloride. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Amiloride is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Amiodarone. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Amiodarone is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Amlodipine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Amlodipine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Amobarbital. The severity of the interaction is moderate. Amobarbital may increase the hypotensive activities of Abaloparatide. The use of barbiturates may increase hypotension. 1,2 Therefore, the concomitant administration of barbiturates and hypotensive agents may lead to dangerous ... |
Drug A is Abaloparatide. Drug B is Amphotericin B. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Amphotericin B is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe... |
Drug A is Abaloparatide. Drug B is Amyl Nitrite. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hyp... |
Drug A is Abaloparatide. Drug B is Apomorphine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Apomorphine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Aripiprazole lauroxil. The severity of the interaction is minor. Aripiprazole lauroxil may increase the hypotensive activities of Abaloparatide. Aripiprazole may cause orthostatic hypotension through antagonism of the α1-adrenergic receptor. 3,2,4 Cases of orthostatic hypotension, pos... |
Drug A is Abaloparatide. Drug B is Aripiprazole. The severity of the interaction is minor. Aripiprazole may increase the hypotensive activities of Abaloparatide. Aripiprazole may cause orthostatic hypotension through antagonism of the α1-adrenergic receptor. 3,2,4 Cases of orthostatic hypotension, postural dizziness, a... |
Drug A is Abaloparatide. Drug B is Arsenic trioxide. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of se... |
Drug A is Abaloparatide. Drug B is Atenolol. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Atenolol is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotension... |
Drug A is Abaloparatide. Drug B is Avanafil. The severity of the interaction is minor. The risk or severity of hypotension can be increased when Avanafil is combined with Abaloparatide. The subject drug is a phosphodiesterase 5 inhibitor which can lower blood pressure. 1 The affected drug can cause hypotension, particu... |
Drug A is Abaloparatide. Drug B is Azilsartan medoxomil. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Abaloparatide is combined with Azilsartan medoxomil. Co-administration of agents that are both associated with a risk for developing hypotension, including cas... |
Drug A is Abaloparatide. Drug B is Benazepril. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Benazepril is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Betaxolol. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Betaxolol is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Bisoprolol. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Bisoprolol is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Bosentan. The severity of the interaction is minor. Abaloparatide may increase the hypotensive activities of Bosentan. The use of two drugs that both lower blood pressure may result in a more pronounced hypotensive effect. Abaloparatide is indicated for the treatment of postmenopausal... |
Drug A is Abaloparatide. Drug B is Bretylium. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Bretylium is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Bromocriptine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Bromocriptine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe h... |
Drug A is Abaloparatide. Drug B is Bumetanide. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Bumetanide is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Bupivacaine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Bupivacaine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Canagliflozin. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Abaloparatide is combined with Canagliflozin. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe h... |
Drug A is Abaloparatide. Drug B is Candesartan cilexetil. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including c... |
Drug A is Abaloparatide. Drug B is Captopril. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Captopril is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Carbetocin. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Carbetocin is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Carvedilol. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Carvedilol is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Celiprolol. The severity of the interaction is minor. Abaloparatide may increase the hypotensive activities of Celiprolol. The use of two drugs that both lower blood pressure may result in a more pronounced hypotensive effect. Abaloparatide is indicated for the treatment of postmenopa... |
Drug A is Abaloparatide. Drug B is Chlorothiazide. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe... |
Drug A is Abaloparatide. Drug B is Chlorpromazine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe... |
Drug A is Abaloparatide. Drug B is Chlorthalidone. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe... |
Drug A is Abaloparatide. Drug B is Cilazapril. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Cilazapril is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Clevidipine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Clevidipine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Clofarabine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Clofarabine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Clomipramine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Clomipramine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hyp... |
Drug A is Abaloparatide. Drug B is Clonidine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Clonidine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Clozapine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Clozapine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Conivaptan. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Conivaptan is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Dapagliflozin. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Abaloparatide is combined with Dapagliflozin. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe h... |
Drug A is Abaloparatide. Drug B is Dasiglucagon. The severity of the interaction is minor. Abaloparatide may increase the hypotensive activities of Dasiglucagon. The use of two drugs that both lower blood pressure may result in a more pronounced hypotensive effect. Abaloparatide is indicated for the treatment of postme... |
Drug A is Abaloparatide. Drug B is Desflurane. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Desflurane is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Dexmedetomidine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of seve... |
Drug A is Abaloparatide. Drug B is Diazoxide. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Diazoxide is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Diclofenamide. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Diclofenamide is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe h... |
Drug A is Abaloparatide. Drug B is Digoxin. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Abaloparatide is combined with Digoxin. Cases of clinical toxicity have been documented with digoxin levels in the therapeutic range. 2 Some studies report that electrolyte... |
Drug A is Abaloparatide. Drug B is Diltiazem. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Diltiazem is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Dinutuximab. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Abaloparatide is combined with Dinutuximab. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Dipyridamole. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Dipyridamole is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hyp... |
Drug A is Abaloparatide. Drug B is Doxazosin. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Doxazosin is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Duloxetine. The severity of the interaction is minor. The risk or severity of orthostatic hypotension and syncope can be increased when Abaloparatide is combined with Duloxetine. Cases of orthostatic hypotension and syncope have been reported with therapeutic doses of duloxetine, whic... |
Drug A is Abaloparatide. Drug B is Empagliflozin. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Abaloparatide is combined with Empagliflozin. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe h... |
Drug A is Abaloparatide. Drug B is Enalapril. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Enalapril is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Enalaprilat. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Abaloparatide is combined with Enalaprilat. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Eplerenone. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Eplerenone is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Epoprostenol. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Epoprostenol is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hyp... |
Drug A is Abaloparatide. Drug B is Eprosartan. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Eprosartan is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Esmolol. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Esmolol is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotension, ... |
Drug A is Abaloparatide. Drug B is Etacrynic acid. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe... |
Drug A is Abaloparatide. Drug B is Ethanol. The severity of the interaction is moderate. Ethanol may increase the hypotensive activities of Abaloparatide. Coadministration of alcohol with hypotensive agents may result in profound or unpredictable hypotensive effects. This may be due to the accumulation of vasodilatory ... |
Drug A is Abaloparatide. Drug B is Felodipine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Felodipine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Fenoldopam. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Fenoldopam is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Fosinopril. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Fosinopril is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Fostamatinib. The severity of the interaction is minor. The risk or severity of hypotension can be increased when Fostamatinib is combined with Abaloparatide. The subject drug is a phosphodiesterase 5 inhibitor which can lower blood pressure. 1 The affected drug can cause hypotension,... |
Drug A is Abaloparatide. Drug B is Furosemide. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Furosemide is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Guanfacine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Guanfacine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Halothane. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Halothane is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Hydralazine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Hydralazine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Hydrochlorothiazide. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases... |
Drug A is Abaloparatide. Drug B is Hydroflumethiazide. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases o... |
Drug A is Abaloparatide. Drug B is Iloprost. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Iloprost is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotension... |
Drug A is Abaloparatide. Drug B is Imipramine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Imipramine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Indapamide. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Indapamide is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Irbesartan. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Irbesartan is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Isocarboxazid. The severity of the interaction is moderate. Isocarboxazid may increase the orthostatic hypotensive activities of Abaloparatide. Incidences of orthostatic hypotension have occurred with monoamine oxidase inhibitors (MAOIs) therapy 1. Co-administration of hypotensive dru... |
Drug A is Abaloparatide. Drug B is Isoflurane. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Isoflurane is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Isosorbide dinitrate. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cas... |
Drug A is Abaloparatide. Drug B is Isosorbide mononitrate. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including... |
Drug A is Abaloparatide. Drug B is Isoxsuprine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Abaloparatide is combined with Isoxsuprine. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Isradipine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Isradipine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Labetalol. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Labetalol is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Lacidipine. The severity of the interaction is moderate. Abaloparatide may increase the hypotensive activities of Lacidipine. Lacidipine by itself is capable of demonstrating prolonged peripheral vasodilation associated with hypotension and tachycardia. There is also a theoretical pos... |
Drug A is Abaloparatide. Drug B is Lercanidipine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Lercanidipine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe h... |
Drug A is Abaloparatide. Drug B is Levamlodipine. The severity of the interaction is minor. Abaloparatide may increase the hypotensive activities of Levamlodipine. The use of two drugs that both lower blood pressure may result in a more pronounced hypotensive effect. Abaloparatide is indicated for the treatment of post... |
Drug A is Abaloparatide. Drug B is Levobupivacaine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of seve... |
Drug A is Abaloparatide. Drug B is Levodopa. The severity of the interaction is minor. The risk or severity of hypotension and orthostatic hypotension can be increased when Abaloparatide is combined with Levodopa. It is known that levodopa-carbidopa therapy with or without the concomitant use of MAO-A or MAO-B inhibito... |
Drug A is Abaloparatide. Drug B is Levosimendan. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Levosimendan is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hyp... |
Drug A is Abaloparatide. Drug B is Linezolid. The severity of the interaction is moderate. Linezolid may increase the orthostatic hypotensive activities of Abaloparatide. Incidences of orthostatic hypotension have occurred with monoamine oxidase inhibitors (MAOIs) therapy 1. Co-administration of hypotensive drugs in pr... |
Drug A is Abaloparatide. Drug B is Lisinopril. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Lisinopril is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Lofexidine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Lofexidine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Losartan. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Losartan is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotension... |
Drug A is Abaloparatide. Drug B is Macitentan. The severity of the interaction is minor. Abaloparatide may increase the hypotensive activities of Macitentan. The use of two drugs that both lower blood pressure may result in a more pronounced hypotensive effect. Abaloparatide is indicated for the treatment of postmenopa... |
Drug A is Abaloparatide. Drug B is Manidipine. The severity of the interaction is minor. Abaloparatide may increase the hypotensive activities of Manidipine. The use of two drugs that both lower blood pressure may result in a more pronounced hypotensive effect. Abaloparatide is indicated for the treatment of postmenopa... |
Drug A is Abaloparatide. Drug B is Mannitol. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Mannitol is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotension... |
Drug A is Abaloparatide. Drug B is Mecamylamine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Mecamylamine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hyp... |
Drug A is Abaloparatide. Drug B is Methazolamide. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Methazolamide is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe h... |
Drug A is Abaloparatide. Drug B is Methohexital. The severity of the interaction is moderate. Methohexital may increase the hypotensive activities of Abaloparatide. The use of barbiturates may increase hypotension. 1,2 Therefore, the concomitant administration of barbiturates and hypotensive agents may lead to dangerou... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.